This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Scott WJ , Howington J , Movsas B
Treatment of stage II non-small cell lung cancer
Chest. 2003 Suppl.;123(1) :188S-201S
AbstractBased on clinical assessment alone, patients with stage 11 non-small cell lung cancer (NSCLC) comprise only 5% of all patients with NSCLC. In addition, patients with stage 11 NSCLC represent a heterogeneous group, since stage 11 consists of patients with T1-2N1 or T3N0 tumors. By definition, patients with tumor invading the chest wall apex, mediastinum, diaphragm, or even the mainstem bronchus may all have T3 tumors. The extent of the data available regarding treatment of each of these different groups is therefore limited. The quality of the data is limited as well, because information often comes from small series of patients. Studies of adjuvant therapy after complete resection of stage 11 NSCLC are an important exception to this generalization, since data from large, randomized studies of adjuvant radiation therapy, chemotherapy, or a combination of the two are available for analysis. Superior sulcus tumors are discussed elsewhere in these guidelines.
NotesScott, WJ,Fox Chase Canc Ctr, Dept Surg Oncol, Sect Thorac Surg Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA Article English